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dictor variables included demographics, treatment type and length, drug usage, 
healthcare setting and experience, status of treatment, aftercare treatment, and 
nursing specialty. Missing data was not considered in the study. After checking for 
all the assumptions, univariate analysis using chi-square test was performed on the 
entire data as well as the subset. All features with significant relationships in the 
univariate analysis were entered in the forward, backward and stepwise multiple 
logistic models to predict the completion of contract by the nurses. All tests were 
conducted at 5% level of significance. Results: All independent variables had a 
significant relationship with the status of CMP. The model using the entire data did 
not converge. The forward logistic model of the subset data showed that drug usage, 
treatment type, status of treatment in contract, annual income and healthcare 
setting had a higher association with the completion of CMP (p-value= 0.1188). The 
backward logistic model showed that aftercare treatment, type of treatment and 
nursing specialty had a significant association with CMP status (p-value = 0.064). The 
stepwise model converged with aftercare treatment having a significant association 
with the CMP status. ConClusions: In this study, the forward logistic model was 
preferred over the backward or the stepwise model to reduce the bias resulting from 
selection of variables and eliminate the resulting quasi-complete separation of data. 
Therefore, this CMP data for nurses was best fit using the forward logistic model.
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objeCtives: To model total health care costs on end-stage renal disease adult 
patients with and without an usual source of care provider and to evaluate 
whether these costs differ between dialysis and transplant patients. Methods: 
Retrospective cross-sectional data from 197 unique adult patients was collected 
for years 2002 to 2011 using the Medical Expenditure Panel Survey conducted on 
American households. Total cost for renal disease patients was modeled using 
the Bayesian mean regression posterior estimates and was followed by comput-
ing predictive values for a new set of observations. Total cost comprised of total 
costs for office based expenditures, prescription drugs, home health care, inpatient 
care, outpatient care, emergency room visits and costs associated with equipment 
and medical supplies. Results: Among the 197 end-stage renal disease patients, 
43% underwent dialysis and 22% underwent transplantation. Overall for the end-
stage renal disease adults, the mean annual costs of care for a patient with an 
usual source of care provider vs. without an usual source of provider was $28,807 
vs. $20,851. In comparison, the mean annual cost of care for a transplant patient 
without a usual source of care was $19,464 and for a dialysis patient was $92,326. 
Transplant patients with a source of care provider can potentially save 23% in annual 
total cost in comparison to patients without any source of care; dialysis patients can 
save 56% of total cost annually. ConClusions: Transplant and dialysis patients 
having an usual source of care provider incurred less health expenditures. In renal 
disease patients, having an usual source of provider has possibly large implications 
for health care cost savings.
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objeCtives: To explore the use of bootstrap model averaging (BOOT) for estimating 
survival curves when conducting parametric survival analysis. Methods: A set of 
four clinical trials in advanced soft tissue sarcoma were identified from a published 
systematic review. Individual patient data for overall survival were estimated from 
digitised Kaplan-Meier curves using a published algorithm. A range of parametric 
survival models (exponential, Weibull, Gompertz, lognormal, log-logistic, Gamma 
and Generalised Gamma) were fitted for each study. One thousand bootstrap sam-
ples of the IPD for each study were taken. The model which minimised the Bayesian 
Information Criterion (BIC) was selected for each sample. The proportions of bootstrap 
samples within which each model was selected were used as the weights for the 
BOOT estimate. These were applied to the mean survival estimates obtained from 
each candidate model applied to the original data set to obtain the weighted average 
BOOT estimate of mean survival for each treatment. Results: Estimates of mean 
survival varied markedly according to the choice of functional form for the parametric 
survival model. There was also considerable uncertainty in the selection of an optimal 
functional form based on the BIC (the bootstrap estimation for the probability that the 
optimal model had been selected varied between 16% and 71% across studies). Using 
the results from the BOOT analysis rather than selecting a single functional form 
reduced the estimated variance in mean survival in all studies. ConClusions: BOOT 
can reduce the variance in mean survival estimates and avoids the need for select-
ing a single functional form for a parametric survival model. Given the considerable 
uncertainty in selecting a functional form and the influence of this process on mean 
survival estimates, BOOT could act as a useful method for addressing uncertainty in 
functional form selection and hence in cost-effectiveness analyses.
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for HbA1c, SBP, BMI, TC, HDL and LDL was predicted as follows. MI: 0.89, 0.90, 1.00, 
0.98, 1.36, 1.00 (UK-68-RE), 0.93, 0.95, 1.00, 1.00, 1.00, 0.93 (UK82-RE) and 0.92, 0.92, 
1.00, 0.99, 1.29, 0.98 (SNDR-RE). Stroke: 0.88, 0.76, 1.00, 0.99, 1.18, 1.00 (UK68-RE), 0.91, 
0.84, 1.00, 1.00, 1.00, 0.97 (UK82-RE) and 0.85, 0.94, 1.00, 0.99, 1.18, 1.00 (SNDR). IHD: 
0.85, 0.89, 0.94, 1.00, 1.00, 1.00 (UK68-RE), 1.00, 0.94, 1.00, 1.00, 1.21, 0.96 (UK82-RE) 
and 0.94, 1.00, 0.98, 0.99, 1.29, 1.00 (SNDR-RE). HF: 0.88, 0.91, 1.00, 0.98, 1.48, 1.00 
(UK68-RE), 1.00, 1.00, 0.93, 1.00, 1.00, 0.98 (UK82-RE) and 0.83, 0.83, 0.94, 0.99, 1.19, 
1.00 (SNDR-RE). ConClusions: The degree to which RF modification influences 
CV risk can vary considerably, dependent on RE selected. The choice of equation 
within a model may influence the predicted health economic benefit associated 
with CV risk factor modification.
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objeCtives: The cost-effectiveness type 2 diabetes mellitus (T2DM) therapies are 
often driven by changes in HbA1c, weight and hypoglycaemia rates. There are a 
number of risk equations available for modeling diabetes complications. The objec-
tive of this study was to attribute the predicted gain in quality adjusted life years 
(QALYs) to HbA1c, weight and hypoglycaemia change for each of the UKPDS-68 
risk equations (UK-68-RE); the UKPDS-82 risk equations (UK-28-RE), the Swedish-
National-Diabetes-Registry RE (S-NDR) and ADVANCE RE (A-RE). Methods: 
Published data on T2DM switching to insulin degludec from either insulin glargine 
or detemir were used. Mean (± SD) baseline profiles were age 62.8 years (± 14.7); 
diabetes duration 16.2 years (± 5.0); HbA1c 9.4% (±1.1); weight 102.8 kg (±23.0) and 1.0 
hypoglycaemia events per week (±1.4). Mean 1-year change in clinical variables was 
HbA1c -0.7% (±0.3); weight -1.3kg (±1.1) and hypoglycaemia events/week -1.0 (±1.3). 
The CDM, with lifetime perspective, was used calculate the incremental QALYs pre-
dicted associated with either the UK-68-RE; UK-82-RE, S-NDR RE and A-RE. Results 
were discounted at 3%. Results: With UK-68-RE total QALYs for insulin degludec 
were 7.747 (QALY gain of 3.306 vs. basal insulin); 2.84%, 97.73% and -0.57% were 
attributable to HbA1c, hypoglycemia and weight change respectively. For UK-82-RE, 
total QALYs were 7.718 (QALY gains 3.306), 2.90%, 97.43% and -0.33% attributable to 
HbA1c, hypoglycemia and weight change respectively. For S-NDR-RE total QALYs 
were 5.937 (QALY gains 2.68), 3.47%, 97.24% and -0.71% attributable to HbA1c, hypo-
glycaemia and weight change. Finally, for ADVANCE-RE total QALYs were 7.035 (QALY 
gains 2.987), 2.31%, 98.32% and -0.63% attributable to HbA1c, hypoglycaemia and 
weight change respectively. ConClusions: HbA1c reduction is not necessarily 
the key driver of health benefit within diabetes models. Validating costs and health 
utilities associated with changes in weight and hypoglycaemia frequency are as 
important as justifying choice of risk equations used.
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objeCtives: In health technology assessment (HTA), decision-makers face increased 
pressures to make earlier decisions. However, in early stages of drug development, 
data on effectiveness of new health technologies measured by the final outcome 
is often limited, especially when measuring the effectiveness of new interventions 
requires long follow-up time. Therefore, shorter-term surrogate endpoints play an 
important role in HTA. Candidate surrogate endpoints do not always proove to be 
perfect. However, when more than one of such endpoints exists, they may jointly fully 
mediate the treatment effect on the final outcome. This study presents methodology 
for evaluation of multiple surrogate endpoints as predictors of the treatment effect on 
the final outcome. Methods: Meta-analytical methods for the evaluation of multiple 
surrogate endpoints are developed. The modelling techniques, developed in Bayesian 
framework, take into account measurement errors of the treatment effects on all out-
comes and the correlations between them. Methods developed are applied to a case 
study in multiple sclerosis (MS) where the relapse rate (RR) and the number of active 
MRI lesions (MRI) are the candidate surrogate endpoints and the final outcome is the 
disability progression (DP). Surrogate endpoints are evaluated by assessing their pre-
dictive value in the cross-validation procedure. Results: Applying bivariate model 
showed a good association between effects on RR and DP. Extending to trivariate case 
to include the effect on MRI increased the precision of the association and reduced the 
heterogeneity. The cross validation gave better predictions, by reducing the intervals 
on average by 14%, when including multiple surrogate endpoints. ConClusions: 
The methods used for combining evidence on multiple surrogate outcomes can lead 
to more precise predictions of the effect on final outcome. Inclusion of multiple sur-
rogate endpoints may lead to a more substantial gain in precision in other disease 
areas, hence leading to faster HTA decisions.
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objeCtives: The main goal of this research is to determine the factors which best 
predict the completion of a nurse substance abuse monitoring program. Methods: 
A retrospective cross sectional analysis was conducted in a state database (Florida) 
of 65,000 nurses enrolled in CMP. The entire dataset and the subset of 10,000 were 
used for analysis. The outcome variable was the status of CMP program. The pre-
